Testing a new communication tool for ovarian cancer patients and their caregivers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study evaluates the Collaborative Agenda-Setting Intervention (CASI), a new communication tool designed for patients with advanced ovarian cancer, their caregivers, and clinicians. The study involves a two-arm, parallel group randomized design where clinicians are assigned to one of two groups, and patients and caregivers are enrolled based on their clinician's group. Participants will undergo screening for eligibility, audio recorded clinic visits, and complete questionnaires over a period of up to 12 weeks for patients and caregivers, and up to 52 weeks for clinicians. The goal is to assess the feasibility and effectiveness of CASI in enhancing communication and care planning.

Why it matters

Who can join: the full rules

Participant Inclusion Criteria:

* At least 18 years old
* Able to speak, understand, and respond to questions written in English
* Willing to be audio recorded
* Have a diagnosis of advanced ovarian cancer (defined as stage III, stage IV, or recurrent disease)
* Be under the care of a participating clinician dyad
* Be scheduled for chemotherapy during the recruitment period
* Be signed up or willing to sign up for Patient Gateway

Caregiver Inclusion Criteria:

* At least 18 years old
* Able to speak, understand, and respond to questions written in English
* Willing to be audio recorded
* Be a family member, partner, or friend of a patient participant with whom the patient participant discusses their cancer care

Clinician Inclusion Criteria:

* Be employed at DFCI as an oncologist, nurse practitioner, or physician assistant
* Take care of at least 4 patients per month with advanced ovarian cancer (defined as stage III, stage IV, or recurrent disease) in the outpatient setting

Participant Exclusion Criteria:

* Age of \<18 years
* Unable to consent

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Rachel Pozzar, PhD — Dana-Farber Cancer Institute
• Study coordinator: Rachel Pozzar, PhD
• Email: Rachel_Pozzar@DFCI.HARVARD.EDU
• Phone: 857-215-0743

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Overcoming immune suppression and rebalancing the immune response in ovarian cancer

  We will try to find and reverse immune suppression by analyzing bone marrow, blood, spleen, peritoneal fluid, and tumor samples from women having surgery for ovarian cancer.

  Recruiting Gynaecologisch Oncologisch Centrum Zuid · Eindhoven, North Brabant · NCT06611072

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Analyzing solid tumors for HLA loss and collecting T cells for CAR T-cell therapy

  This study is testing how often solid tumors lose a key protein that helps the immune system recognize them, while also collecting T cells from patients with high-risk cancers to prepare for future CAR T-cell therapy.

  Recruiting at 13 sites A2 Biotherapeutics Inc. · Gilbert, Arizona and 15 other locations · NCT04981119

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Using ultrasound microvessel imaging to evaluate ovarian and adnexal lesions

  This test tries to see if ultrasound microvessel imaging can better detect small blood vessels in adults scheduled for surgery for ovarian or adnexal lesions.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07280312

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.